New drug aims to boost energy in rare muscle disease
Disease control
Completed
This study tested a daily injection called elamipretide for adults with a rare muscle disease caused by faulty mitochondrial DNA. The goal was to see if it improves walking distance and muscle function. 102 people took part in this 48-week trial, comparing the drug to a placebo.
Phase: PHASE3 • Sponsor: Stealth BioTherapeutics Inc. • Aim: Disease control
Last updated May 08, 2026 12:02 UTC